Edwards Lifesciences's EPS (Basic) for the
three
months ended in Mar. 2026 was CHF0.52.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.51.
During the past 12 months, Edwards Lifesciences's average EPS without NRIGrowth Rate was 3.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 1.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 5.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Edwards Lifesciences's highest 3-Year average EPS without NRI Growth Rate was 31.30% per year. The lowest was 1.10% per year. And the median was 13.70% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Edwards Lifesciences EPS (Diluted) Related Terms
Edwards Lifesciences EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EW vs DXCM, GEHC, BSX: EPS (Diluted) Comparison
For the Medical Devices subindustry, Edwards Lifesciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Edwards Lifesciences's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (XSWX:EW) has a EPS (Diluted) of CHF1.51 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' EPS (Diluted) too high?
Edwards Lifesciences' current EPS (Diluted) is CHF1.51. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EPS (Diluted) compare to DXCM and GEHC?
Edwards Lifesciences' EPS (Diluted) of CHF1.51 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Devices & Instruments company?
A good EPS (Diluted) depends on the Medical Devices & Instruments industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current EPS (Diluted) is CHF1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current EPS (Diluted) of CHF1.51. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current EPS (Diluted) is CHF1.51. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current EPS (Diluted) is CHF1.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
EPS (Diluted): CHF1.51
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
